Literature DB >> 33552482

Nonalcoholic Fatty Liver Disease and Recent Guideline Updates.

Yumi Ando1, Janice H Jou1,2.   

Abstract

Watch a video presentation of this article.
© 2021 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2021        PMID： 33552482      PMCID： PMC7849298          DOI： 10.1002/cld.1045

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  15 in total

1.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

Review 2.  The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.

Authors:  Shiv Chitturi; Vincent Wai-Sun Wong; Wah-Kheong Chan; Grace Lai-Hung Wong; Simon Kin-Hung Wong; Jose Sollano; Yen-Hsuan Ni; Chun-Jen Liu; Yu-Cheng Lin; Laurentius Adrianto Lesmana; Seung Up Kim; Etsuko Hashimoto; Masahide Hamaguchi; Khean-Lee Goh; Jiangao Fan; Ajay Duseja; Yock Young Dan; Yogesh Chawla; Geoff Farrell; Henry Lik-Yuen Chan
Journal:  J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 4.029

3.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  J Hepatol       Date:  2016-04-07       Impact factor: 25.083

Review 4.  Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.

Authors:  Vincent Wai-Sun Wong; Wah-Kheong Chan; Shiv Chitturi; Yogesh Chawla; Yock Young Dan; Ajay Duseja; Jiangao Fan; Khean-Lee Goh; Masahide Hamaguchi; Etsuko Hashimoto; Seung Up Kim; Laurentius Adrianto Lesmana; Yu-Cheng Lin; Chun-Jen Liu; Yen-Hsuan Ni; Jose Sollano; Simon Kin-Hung Wong; Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Geoff Farrell
Journal:  J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 4.029

Review 5.  MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.

Authors:  Mohammed Eslam; Arun J Sanyal; Jacob George
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

6.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

7.  Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.

Authors:  Sahil Mittal; Hashem B El-Serag; Yvonne H Sada; Fasiha Kanwal; Zhigang Duan; Sarah Temple; Sarah B May; Jennifer R Kramer; Peter A Richardson; Jessica A Davila
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-18       Impact factor: 11.382

8.  Nonalcoholic fatty liver disease is underrecognized in the primary care setting.

Authors:  Pierre Blais; Nisreen Husain; Jennifer R Kramer; Marc Kowalkowski; Hashem El-Serag; Fasiha Kanwal
Journal:  Am J Gastroenterol       Date:  2014-06-03       Impact factor: 10.864

9.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

Authors:  Giovanni Targher; Christopher D Byrne; Amedeo Lonardo; Giacomo Zoppini; Corrado Barbui
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

10.  Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.

Authors:  Robert J Wong; Tram Tran; Harvey Kaufman; Justin Niles; Robert Gish
Journal:  PLoS One       Date:  2019-08-01       Impact factor: 3.240
View more
  17 in total

1.  Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Authors:  Ana Luisa Ordóñez-Vázquez; Sofía Murúa Beltrán-Gall; Shreya C Pal; Nahum Méndez-Sánchez
Journal:  Med Sci Monit       Date:  2022-09-12

2.  The role of diet in the management of MAFLD-why does a new disease require a novel, individualized approach?

Authors:  Alina Kurylowicz
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

3.  Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey.

Authors:  Mary Rinella; Donna R Cryer; Amy Articolo; Travis Fisher; Jennifer Schneider; Karl Nadolsky
Journal:  BMC Gastroenterol       Date:  2022-07-10       Impact factor: 2.847

4.  Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease.

Authors:  Eleonora Scorletti; Kate Townsend Creasy; Marijana Vujkovic; Mara Vell; Inuk Zandvakili; Daniel J Rader; Kai Markus Schneider; Carolin V Schneider
Journal:  Am J Gastroenterol       Date:  2022-03-14       Impact factor: 12.045

5.  Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis.

Authors:  Jiaxin Liu; Bo Dong; Lin Yang; Wei Huang; Songqi Tang
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

6.  Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE).

Authors:  Wayne Eskridge; John M Vierling; Wayne Gosbee; Gabriella A Wan; May-Linh Hyunh; Henry E Chang
Journal:  PLoS One       Date:  2021-11-30       Impact factor: 3.240

7.  Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among Type-2 diabetics.

Authors:  Alia Ali; Muhammad Joher Amin; Muhammad Uthman Ahmed; Azeem Taj; Muhammad Aasim; Elsa Tabrez
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

Review 8.  Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Authors:  Thaninee Prasoppokakorn; Panyavee Pitisuttithum; Sombat Treeprasertsuk
Journal:  J Clin Transl Hepatol       Date:  2021-07-28

9.  Ethyl Acetate Fraction of Amomum villosum var. xanthioides Attenuates Hepatic Endoplasmic Reticulum Stress-Induced Non-Alcoholic Steatohepatitis via Improvement of Antioxidant Capacities.

Authors:  Jung-Hyo Cho; Jong-Suk Lee; Hyeong-Geug Kim; Hye Won Lee; Zhigang Fang; Hyeok-Hee Kwon; Dong Woon Kim; Chang-Min Lee; Jin-Woo Jeong
Journal:  Antioxidants (Basel)       Date:  2021-06-23

10.  Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease.

Authors:  Lauren A Newman; Zivile Useckaite; Jillian Johnson; Michael J Sorich; Ashley M Hopkins; Andrew Rowland
Journal:  Biomedicines       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.